BTAI - BioXcel Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BTAI is currently covered by 7 analysts with an average price target of $59.67. This is a potential upside of $56.26 (1649.85%) from yesterday's end of day stock price of $3.41.

BioXcel Therapeutics's activity chart (see below) currently has 83 price targets and 89 ratings on display. The stock rating distribution of BTAI is 70.37% BUY, 25.93% HOLD and 3.7% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 63.84% with an average time for these price targets to be met of 289.8 days.

Highest price target for BTAI is $16, Lowest price target is $4, average price target is $21.6.

Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 23-Jun-2025. First documented stock forecast 02-Apr-2018.

Currently out of the existing stock ratings of BTAI, 19 are a BUY (70.37%), 7 are a HOLD (25.93%), 1 are a SELL (3.7%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$8

$4.59 (134.60%)

1 months 17 days ago
(23-Jun-2025)

6/19 (31.58%)

$6.35 (384.85%)

564

Sell

$4

$0.59 (17.30%)

$23

7 months 2 days ago
(07-Jan-2025)

4/4 (100%)

$-3.54 (-46.95%)

378

Buy

7 months 3 days ago
(06-Jan-2025)

9/11 (81.82%)

$-52.4 (-74.43%)

446

Hold

$16

$12.59 (369.21%)

$64

11 months 28 days ago
(12-Aug-2024)

7/10 (70%)

$5.48 (52.09%)

48

Hold

$16

$12.59 (369.21%)

$56

1 years ago
(09-Aug-2024)

1/4 (25%)

$4.3 (36.75%)

280

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BTAI (BioXcel Therapeutics) average time for price targets to be met?

On average it took 289.8 days on average for the stock forecasts to be realized with a an average price target met ratio 63.84

Which analyst has the current highest performing score on BTAI (BioXcel Therapeutics) with a proven track record?

RAGHURAM SELVARAJU

Which analyst has the most public recommendations on BTAI (BioXcel Therapeutics)?

Raghuram Selvaraju works at HC WAINWRIGHT and has 3 price targets and 16 ratings on BTAI

Which analyst is the currently most bullish on BTAI (BioXcel Therapeutics)?

Do Kim with highest potential upside - $1660.59

Which analyst is the currently most reserved on BTAI (BioXcel Therapeutics)?

Sumant Kulkarni with lowest potential downside - -$0

BioXcel Therapeutics in the News

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced completion of the...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?